Abatacept in B7-1–Positive Proteinuric Kidney Disease
| Autor: | Yu, Chih-Chuan, Fornoni, Alessia, Weins, Astrid, Hakroush, Samy, Maiguel, Dony, Sageshima, Junichiro, Chen, Linda, Ciancio, Gaetano, Faridi, Mohd Hafeez, Behr, Daniel, Campbell, Kirk N, Chang, Jer-Ming, Chen, Hung-Chun, Oh, Jun, Faul, Christian, Arnaout, M Amin, Fiorina, Paolo, Gupta, Vineet, Greka, Anna, Burke, George W, Mundel, Peter |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Immunoconjugates Kidney Disease Adolescent Renal and urogenital Urology urologic and male genital diseases Medical and Health Sciences Article Focal Segmental Abatacept Young Adult Glomerulosclerosis Rare Diseases General & Internal Medicine medicine Humans Child urogenital system Glomerulosclerosis Focal Segmental Podocytes business.industry General Medicine medicine.disease female genital diseases and pregnancy complications Proteinuria B7-1 Antigen Female business Biomarkers medicine.drug Kidney disease |
| Zdroj: | The New England journal of medicine, vol 369, iss 25 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmc1400502 |
| Popis: | Abatacept (cytotoxic T-lymphocyte–associated antigen 4–immunoglobulin fusion protein [CTLA-4–Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1–positive glomerular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|